Tolerability Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tolerability trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tolerability Trial Today - Breaking & Trending Today

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress - Unicycive Therapeutics (NASDAQ:UNCY)

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress - Unicycive Therapeutics (NASDAQ:UNCY)
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Satya Medicherla , Shalabh Gupta , European Renal Association , Shire International Licensing , Unicycive Therapeutics Inc , Reason Research , Exchange Commission , Company Or Unicycive , Moral Administration , Drug Administration , Renal Associates , Preclinical Model , Hyperphosphatemia Demonstrate , Relative Potency , Potential Candidate , Delayed Graft Function Related , Acute Kidney Injury , Chief Executive Officer , Enhanced Urinary Phosphorous Reduction , Comparative Study , Oxylanthanum Carbonate , Vice President , Preclinical Pharmacology , End Stage Kidney Disease ,

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that multiple presentations will be delivered on the Company’s product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden. Shalabh Gupta, MD, Chief Execu ....

United States , United Kingdom , Satya Medicherla , Shalabh Gupta , Exchange Commission , European Renal Association , Drug Administration , Unicycive Therapeutics Inc , Company Or Unicycive , Reason Research , Shire International Licensing , Renal Associates , Moral Administration , Chief Executive Officer , Urinary Phosphorous Reduction , Comparative Study , Oxylanthanum Carbonate , Vice President , Preclinical Pharmacology , End Stage Kidney Disease , Tolerability Trial , Acute Kidney Injury , Rat Model , Delayed Graft , End Stage Renal Disease , Delayed Graft Function ,